Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haematitum
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Haematitum (代赭石, Dai Zhe Shi) is a mineral-based traditional Chinese medicine primarily composed of ferric oxide (Fe2O3). It is officially listed in the Chinese Pharmacopoeia and is traditionally used to "subdue liver yang," "direct qi downward," and "stop bleeding." Clinically, it is employed to treat conditions such as belching, vomiting, hiccups, asthma, and various types of hemorrhage. While effective, it is considered slightly toxic and is often processed by calcination (calcined Haematitum) to reduce toxicity and improve friability for decoction. Recent studies have explored its potential for multi-organ toxicity (particularly pulmonary) at high doses and its role in complex TCM formulas like Xuanfu Daizhe Decoction for gastrointestinal disorders.
- Other names
- 代赭石Dai Zhe ShiHematiteRed OchreFerric oxideHematitum
Beyond the preview
Go deeper on haematitum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haematitum.